A research team has evaluated the real-world impact of a community-based pneumococcal vaccination support program for older ...

Findings based on efforts in Sera Town, Japan showed the pneumococcal vaccination support program reversed the previously ...

A research team has evaluated the real-world impact of a community-based pneumococcal vaccination support program for older adults conducted in Sera ...

Pneumonia is a form of acute respiratory infection, that is common in all age groups and can cause mild to life-threatening ...

Report Ocean’s latest analysis delves into the “Vietnam 23 Valent Pneumococcal Polysaccharide Vaccine Market” Report from 2024 to 2032, covering an array of market facets such as characteristics, size ...

CAPVAXIVE is Merck’s approved 21-valent pneumococcal conjugate vaccine indicated for active immunization for the prevention of invasive disease and pneumonia in adults 18 years of age and older.

RAHWAY, N.J., October 16, 2024--Merck’s CAPVAXIVE (Pneumo. 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease ...

The 23-valent polysaccharide vaccine may induce a protective immune response against invasive pneumococcal diseases in the elderly population. Our study demonstrated that the mean increase in ...

In the STRIDE-10 study, Merck’s V116—which is a 21-valent conjugate vaccine designed for adults—stacked up favorably against PPSV23, a 23-valent polysaccharide vaccine that was approved back ...

There have been some reports of necrosis at the injection site following receipt of the 23-valent pneumococcal vaccine, but the vaccine’s overall benefit-risk balance “remains favorable ...